Brief: GlycoMimetics Launches Trial To Evaluate Co's Drug Candidate In AML Patients
22/07/2021 14:25
July 22 (Reuters) - GlycoMimetics Inc GLYC.O :
* GLYCOMIMETICS INC - TRIAL LAUNCHES TO EVALUATE
GLYCOMIMETICS'
UPROLESELAN ADDED TO CLADRIBINE PLUS LOW-DOSE CYTARABINE IN AML
PATIENTS
Source text for Eikon: ID:nBw6TC1cVa
Further company coverage: GLYC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Crescent Biopharma
See all newsBrief: Crescent Biopharma - Potential To Initiate First CR-001 Phase 3 Study In Early 2028
Brief: Crescent Biopharma Announces FDA Clearance Of Ind Application For CR-002, A Pd-L1-Targeted Topoisomerase Inhibitor Adc, For The Treatment Of Solid Tumors
Crescent Biopharma posts smaller-than-expected Q2 net loss
U.S. STOCKS ON THE MOVE-Cintas, Veradermics
Crescent Biopharma slips on $125 mln share offering